Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNTI Senti Biosciences, Inc.

Trading 03-26 15:14:12 EDT

0.8814

+0.0003

+0.03%

High0.8957	Low0.8723	Vol43.37K
Open0.8900	D1 Closing0.8811	Amplitude2.66%
Mkt Cap23.06M	Tradable Cap8.44M	Total Shares26.16M
T/O38.40K	T/O Rate0.45%	Tradable Shares9.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNTI","market":"US","secType":"STK","nameCN":"Senti Biosciences, Inc.","latestPrice":0.8814,"timestamp":1774552286158,"preClose":0.8811,"halted":0,"volume":43367,"delay":0,"changeRate":0.0003404834865508648,"floatShares":9575679,"shares":26160206,"eps":-2.87,"marketStatus":"Trading","change":0.0003,"latestTime":"03-26 15:14:12 EDT","open":0.89,"high":0.8957,"low":0.8723,"amount":38398.4905137,"amplitude":0.026558,"askPrice":0.8819,"askSize":274,"bidPrice":0.8733,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.87,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1622001600000,"exchange":"NASDAQ","adjPreClose":0.8811,"preHourTrading":{"tag":"盘前","latestPrice":0.9,"preClose":0.8811,"latestTime":"09:27 EDT","volume":2097,"amount":1858.7394891000001,"timestamp":1774531668203,"change":0.0189,"changeRate":0.02145,"amplitude":0.031665},"postHourTrading":{"tag":"盘后","latestPrice":0.8811,"preClose":0.8811,"latestTime":"19:59 EDT","volume":99,"amount":87.3975,"timestamp":1774483175454,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.396617},"requestUrl":"/m/hq/s/SNTI","defaultTab":"news","newsList":[{"id":"2621706455","title":"Senti Biosciences to present SENTI-202 Phase 1 data at 11th Annual Innate Killer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706455","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706455?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:05","pubTimestamp":1774271107,"startTime":"0","endTime":"0","summary":"Senti Bio will present clinical and translational data on its SENTI-202 program at the 11th Annual Innate Killer Conference on March 24-25, 2026, in San Diego, California.Rochelle Emery is scheduled to give a clinical data presentation on Phase I results from the SENTI-202-101 study.Brian Garrison is scheduled to lead a workshop on biomarker discovery and translational tools for NK cell therapy development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5rh7BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"gpt_icon":0},{"id":"2620949974","title":"Senti Biosciences Inc  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620949974","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620949974?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:17","pubTimestamp":1773692230,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc  expected to post a loss of41cents a share - Earnings Preview Senti Biosciences Inc SNTI.OQ SNTI.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N404285:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"gpt_icon":0},{"id":"2616325497","title":"Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325497","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325497?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:06","pubTimestamp":1772546760,"startTime":"0","endTime":"0","summary":"Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference               Senti Biosciences, Inc. will present at the Leerink Partners 2026 Global Healthcare Conferenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1nPf8w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","BK4207","BK4539","SG9999014021.USD","BK4585","SG9999014005.SGD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4112","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","MNSH","LU0314104364.USD","SNTI","BK4139"],"gpt_icon":0},{"id":"2613717404","title":"Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:15","pubTimestamp":1771942540,"startTime":"0","endTime":"0","summary":"data=S_Eelhm-6r8Uxqy3crHpe0FIyHrfKjFY4dalpcGWx4UGhgnPVJbubxcbPbCVp_8f8BXu63fCVRhw-wFe_xjW6g==), and live video is available here: https://www.globenewswire.com/Tracker?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9BSlkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","BK4139","BK4112","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","BK4585","IE00B3QW5Z07.USD","SNTI","BK4588","LU2095319765.USD","SG9999014021.USD","BK4539","LU2210150020.SGD"],"gpt_icon":0},{"id":"2612267613","title":"Senti Biosciences Joins Cell & Gene Live Virtual Event on Emerging Cell Therapy Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2612267613","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612267613?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:50","pubTimestamp":1771595409,"startTime":"0","endTime":"0","summary":"Senti Biosciences participated in the Cell & Gene Live virtual event on Feb. 19, 2026, joining industry leaders to discuss emerging technologies aimed at improving the design, development, and translation of cell therapies. The company highlighted how its Gene Circuit platform is intended to enhance precision, control, and functionality in engineered cell therapies, including its logic-gated SENTI-202 program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5vzFQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK0239","NDAQ","600645","IE00BKPKM429.USD","SG9999014005.SGD","BK0188","BK4588","BK4139","SNTI","BK0216","SG9999014013.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK0042","LU2210150020.SGD","BK4539","IE00B64PRP62.GBP","BK4585","BK0046","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112"],"gpt_icon":0},{"id":"2610953226","title":"BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953226","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953226?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:03","pubTimestamp":1770818606,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202 Feb 11 (Reuters) - Senti Biosciences Inc SNTI.O:SENTI BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1 CLINICAL TRIAL OF ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA4PGH1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"gpt_icon":0},{"id":"2610958992","title":"Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610958992?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:35","pubTimestamp":1770816909,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia . The company recently presented positive clinical data from this study at the American Society of Hematology  Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy  designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbzllmp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4588","BK4539","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4139","SG9999014021.USD","SNTI","BK4112","LU2210149790.SGD","SG9999014005.SGD","BK4585"],"gpt_icon":0},{"id":"2610586619","title":"Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of Senti-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610586619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610586619?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:35","pubTimestamp":1770816900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA4PGH1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","SNTI"],"gpt_icon":0},{"id":"2608872895","title":"Senti Biosciences to Present Gene Circuit Platform at Healthcare Conference Taipei","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872895","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872895?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:00","pubTimestamp":1770127218,"startTime":"0","endTime":"0","summary":"Senti Biosciences, Inc. will deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei. The event will take place on February 10-11, 2026, at the Regent Taipei Hotel. Senti’s CEO, Dr. Timothy Lu, is scheduled to present on February 10, 2026, from 10:30 AM to 10:40 AM local time, highlighting the company’s Gene Circuit technology platform and strategic priorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL1MWrl6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","BK4539","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","BK4585","SG9999014005.SGD","LU0314104364.USD","NDAQ","BK4139","SG9999014013.SGD","IE00BGHQF748.EUR","SNTI","SG9999014039.USD"],"gpt_icon":0},{"id":"2603143476","title":"Press Release: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603143476","media":"Dow Jones","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603143476?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:15","pubTimestamp":1768400100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026  -- Senti Biosciences, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment.Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Sen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4117","ASH","SNTI","BK4107","LU2463526074.USD","BK4109","BK4539","AFG"],"gpt_icon":0},{"id":"2602379766","title":"Senti Biosciences CEO to Join Cell and Gene Therapy Panel at Biotech Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379766","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379766?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:55","pubTimestamp":1767966908,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc. will participate in a panel presentation at Biotech Showcase 2026, taking place January 12-14, 2026, in San Francisco, CA. Dr. Timothy Lu, Co-Founder and CEO of Senti Bio, will join other industry leaders for a panel titled \"Engineering the Future: Advances in Cell and Gene Therapies,\" scheduled for Tuesday, January 13th at 8:00 AM PT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL4xS55R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","SNTI","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","BK4539","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4112","NDAQ","BK4588"],"gpt_icon":0},{"id":"2592182043","title":"Senti Biosciences Grants Stock Options to New Employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182043","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182043?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:30","pubTimestamp":1766097009,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc. has granted a new employee stock options to purchase a total of 13,680 shares of the company's common stock at an exercise price of $1.31 per share. These stock options were issued under the company's Amended and Restated 2022 Inducement Equity Plan, which was initially adopted by the board of directors on August 5, 2022.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9X4l5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","NDAQ","LU2095319765.USD","SNTI","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","BK4139","SG9999014039.USD","LU2210149790.SGD","BK4585","BK4539","LU2210150020.SGD","SG9999014013.SGD","BK4112","SG9999014021.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590582143","title":"Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590582143","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590582143?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:55","pubTimestamp":1765371323,"startTime":"0","endTime":"0","summary":"Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNTI","BK4139","BK4539"],"gpt_icon":0},{"id":"2590329129","title":"Senti Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590329129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590329129?lang=en_us&edition=fundamental","pubTime":"2025-12-10 04:17","pubTimestamp":1765311420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 15:17 ET (20:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"gpt_icon":0},{"id":"2590326220","title":"Why Is Gene Therapy Focused Senti Bio Stock Falling Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326220","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590326220?lang=en_us&edition=fundamental","pubTime":"2025-12-10 02:34","pubTimestamp":1765305240,"startTime":"0","endTime":"0","summary":"Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable remissions, and a favorable safety profile.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ORR","SNTI","ASH","BK4161","CR","BK4139","BK4109","LU2463526074.USD","BK4539"],"gpt_icon":0},{"id":"1171196676","title":"Senti Biosciences (SNTI.US) Surges Over 7% at Open on Positive Phase 1 SENTI-202 Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1171196676","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171196676?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:54","pubTimestamp":1765292052,"startTime":"0","endTime":"0","summary":"Senti Biosciences, Inc. (SNTI.US) opened more than 7% higher on Tuesday, trading at $2.54. The surge follows the company's updated Phase 1 SENTI-202 trial data for relapsed/refractory acute myeloid...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"gpt_icon":0},{"id":"2590343235","title":"Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343235","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343235?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:02","pubTimestamp":1765281761,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc. has announced that the U.S. Food and Drug Administration  has granted Regenerative Medicine Advanced Therapy  designation to SENTI-202, the company's investigational off-the-shelf chimeric antigen receptor natural killer  cell therapy, for the treatment of relapsed or refractory hematologic malignancies, including acute myeloid leukemia . The RMAT designation was based on data from Senti Bio's ongoing Phase 1 clinical trial in adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies. Updated clinical data from this trial were presented orally and in poster form at the American Society of Hematology  Annual Meeting on December 8, 2025. The results showed a 50% overall response rate and a 42% complete remission or complete remission with partial hematologic recovery at the recommended Phase 2 dose, with a median duration of composite complete remission of 7.6 months across all patients. SENTI-202 has also received Orphan Drug ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9lCDFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SNTI","SG9999014021.USD","SG9999014013.SGD","BK4112","BK4539","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","BK4585","SG9999014005.SGD","BK4139","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2590431493","title":"Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Senti-202 in the Treatment of Adults With Relapsed or Refractory Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2590431493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590431493?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA7QWPSX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNTI","BK4539"],"gpt_icon":0},{"id":"2585149026","title":"Senti Biosciences Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149026","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149026?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:44","pubTimestamp":1763736240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 09:44 ET (14:44 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"gpt_icon":0},{"id":"2585454891","title":"Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2585454891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585454891?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:35","pubTimestamp":1763732130,"startTime":"0","endTime":"0","summary":"Senti Biosciences (SNTI) has received a new Buy rating, initiated by Leerink Partners analyst, Jeffrey La Rosa. Jeffrey La Rosa has given his Buy r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-senti-biosciences-innovative-gene-circuit-platform-shows-promise-in-aml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-senti-biosciences-innovative-gene-circuit-platform-shows-promise-in-aml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","SNTI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sentibio.com","stockEarnings":[{"period":"1week","weight":-0.0919},{"period":"1month","weight":0.0145},{"period":"3month","weight":-0.2338},{"period":"6month","weight":-0.3661},{"period":"1year","weight":-0.7511},{"period":"ytd","weight":-0.1528}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.037903},{"month":2,"riseRate":0.2,"avgChangeRate":-0.117173},{"month":3,"riseRate":0.2,"avgChangeRate":-0.059129},{"month":4,"riseRate":0.25,"avgChangeRate":-0.055926},{"month":5,"riseRate":0.25,"avgChangeRate":-0.078726},{"month":6,"riseRate":0,"avgChangeRate":-0.301397},{"month":7,"riseRate":0.4,"avgChangeRate":0.120052},{"month":8,"riseRate":0.4,"avgChangeRate":-0.119944},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088688},{"month":10,"riseRate":0.6,"avgChangeRate":0.032318},{"month":11,"riseRate":0.4,"avgChangeRate":0.12033},{"month":12,"riseRate":0.4,"avgChangeRate":0.047383}],"exchange":"NASDAQ","name":"Senti Biosciences, Inc.","nameEN":"Senti Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Senti Biosciences, Inc.,SNTI,Senti Biosciences, Inc.股票,Senti Biosciences, Inc.股票老虎,Senti Biosciences, Inc.股票老虎国际,Senti Biosciences, Inc.行情,Senti Biosciences, Inc.股票行情,Senti Biosciences, Inc.股价,Senti Biosciences, Inc.股市,Senti Biosciences, Inc.股票价格,Senti Biosciences, Inc.股票交易,Senti Biosciences, Inc.股票购买,Senti Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction